Psagot Investment House LTD Decreased Its Gilead Sci(Gild (GILD) Stake by $5.87 Million as Shares Declined

June 27, 2018 - By Carey Conley

Gilead Sciences, Inc. (NASDAQ:GILD) Corporate LogoBig Money Sentiment increased to 0.88 in 2018 Q1. It has change of 0.08, from 2017Q4’s 0.8. The ratio improved due to GILD positioning: 71 sold and 519 reduced. 114 funds bought stakes and 404 increased stakes. Investors holded 972.68 million in 2017Q4 but now own 976.44 million shares or 0.39% more. Professional Advisory Ser invested 0.13% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Muhlenkamp reported 222,377 shs. Stillwater Management Ltd Liability Com invested 1.42% in Gilead Sciences, Inc. (NASDAQ:GILD). Sunbelt Secs stated it has 0.49% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Cohen Lawrence B owns 22,800 shs for 1.15% of their capital. 1.15 million were accumulated by Pointstate Capital Lp. Diligent Ltd reported 3,201 shs or 0.15% of all its holdings. Ghp has invested 0.07% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Biltmore Wealth Limited Liability Com invested in 0.37% or 5,236 shs. Perella Weinberg Partners Cap Mgmt LP invested in 0.12% or 35,790 shs. British Columbia Investment Management Corporation reported 724,929 shs. Commercial Bank Of Montreal Can owns 0.22% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 3.34M shs. Wealthfront owns 27,453 shs. Farmers Savings Bank stated it has 0.03% of its capital in Gilead Sciences, Inc. (NASDAQ:GILD). Fred Alger Mgmt holds 16,300 shs or 0.01% of its capital.

GILD registered $48.21 million net activity with 0 insider buys and 23 insider sales since January 2, 2018. 60,000 shs were sold by WILSON GAYLE E, worth $4.68M. On Thursday, February 1 the insider Alton Gregg H sold $2.09M. MARTIN JOHN C sold $3.68M worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 50,000 shs on Tuesday, January 2. $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Washington Robin L. Meyers James R had sold 100,000 shs worth $8.02 million.

Psagot Investment House Ltd’s stake in Gilead Sci(Gild (GILD) is decreased by 27.32% based on its latest 2018Q1 regulatory filing with the SEC. 78,263 shares were sold by Psagot Investment House Ltd as the company’s stock declined 17.62% with the market. The institutional investor is holding 208,205 shares, compared to the 286,468 from the previous quarter. And the reported value of the health care company is $15.70 million for the 2018Q1. $91.34B is the market cap of Gilead Sci(Gild. The stock decreased 1.25% or $0.89 during the last trading session, touching $70.25.Gilead Sciences, Inc. has volume of 4.60M shares. Since June 27, 2017 GILD has risen 4.37% and is uptrending. GILD underperformed by 8.20% the S&P500.

About $2.31B US Long portfolio Psagot Investment House Ltd manages. It rose its stake in Visa Inc (V Us) (NYSE:V) by 128,801 shares to 155,810 shares, valued at $18.64M in 2018Q1, according to the filing. Psagot Investment House Ltd has risen its stake in Vanguard(Vcsh) (VCSH) and also increased its holding in Global X(Lit) by 206,216 shares in the quarter, for a total of 230,216 shares.

On July, 25. Investors expect Gilead Sciences, Inc. (NASDAQ:GILD) to reveal its quarterly earnings, as reported by Faxor. Analysts have expectation on stock’s earnings per share of $1.42. That’s down 43.43 % from last year’s $2.51 earnings per share. The profit will be $1.85 billion for GILD if $1.42 earnings per share becomes true. After $1.37 EPS report previous quarter, Wall Street now predicts 3.65 % EPS growth of Gilead Sciences, Inc..

For more Gilead Sciences, Inc. (NASDAQ:GILD) news published briefly go to: Streetinsider.com, Nasdaq.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Gilead Sciences (GILD) Announces EC Granted Marketing Authorization for its Biktarvy for Treatment of HIV-1 Infection” published on June 25, 2018, “5 Top Stocks to Buy in June” on June 01, 2018, “Gilead: Growth Pick For Your Portfolio” with a publish date: June 15, 2018, “Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)” and the last “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” with publication date: May 30, 2018.

Gilead Sciences, Inc. (NASDAQ:GILD) Ratings Coverage

A total of 15 analysts rate Gilead Sciences (NASDAQ:GILD) as follows: 10 “Buy”, 5 “Hold” and 0 “Sell”. Тherefore 67% are bullish. The firm has $103.0 highest and $7200 lowest target. The avg target $88.07 is 25.37% above the last ($70.25) price. (NASDAQ:GILD) has 23 ratings reports on Jun 27, 2018 according to StockzIntelligence. In Wednesday, February 7 report RBC Capital Markets maintained the stock with “Buy” rating. On Wednesday, February 7 Morgan Stanley maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating. Morgan Stanley has “Equal-Weight” rating and $84 target. On Wednesday, May 30 the rating was initiated by Piper Jaffray with “Buy”. On Wednesday, May 2 the rating was maintained by Leerink Swann with “Hold”. In Tuesday, February 6 report Maxim Group maintained it with “Buy” rating and $94.0 target. On Friday, January 26 the stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given by Jefferies. On Wednesday, February 7 Leerink Swann maintained Gilead Sciences, Inc. (NASDAQ:GILD) with “Market Perform” rating. On Wednesday, February 7 the firm has “Buy” rating given by Cowen & Co. On Tuesday, January 30 the stock of Gilead Sciences, Inc. (NASDAQ:GILD) has “Buy” rating given by Citigroup. On Wednesday, January 3 Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) with “Hold” rating.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.